Page 8 - Roche Hemlibra Non-inhibitors - Product Monograph

Non drug related direct costs for hemophilia include:
• Hematologist and other specialist consultations
• Medical tests and examinations
• Bleed-related management (medications, hospitalization,
physiotherapy, radiotherapy, outpatient consultation, outpatient
nursing, etc.)

Mean annual indirect costs for hemophilia include:

• Loss of earnings • Personal aids
• Transfer payments • Alternative therapies
• Over the counter medications • Transport
• Devices

COST OF ILLNESS
Local data was generated by a ‘burden of disease model’ for hemophilia A patients in UAE. The

cost of illness study which was designed to assess the clinical, economic and humanistic burden
of hemophilia A in UAE, suggests that:

• The management of hemophilia in UAE is estimated to be 93,926,563 AED annually
• 75.14% of which (70,575,427 AED) is spent on drug acquisition cost
• 24.86% of which (23,351,136 AED) is spent on non-drug acquisition costs, mainly to manage the
bleeds resulting from insufficient protection for the patient using factor replacement therapy

More than 23.3 million AED is spent on the management of bleeds, despite the high rate of
adequate prophylaxis with factor replacement. Prophylaxis rate is estimated to be 96%.
In 5 years’ time horizon, more than 116 million AED are spent on the management of bleeds, that
are not captured in the drug acquisition cost.

Non-drug acquisition costs include:

Drug Bleed Orthopedic Adverse
administration cost management surgery events

Reports have shown that UAE has 68 hemophilia A patients without inhibitors (which represents 92% of
the total hemophilia A patients in UAE).

The management of hemophilia A without inhibitors in UAE is estimated to be 83.822,027 AED annually

HEMLIBRA Monograph-Non-inhibitors | 06
®